- Home
- MVO vs CRVO Comparison
MVO vs CRVO Comparison
Compare MVO & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MVO | CRVO |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.9M | 47.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MVO | CRVO |
|---|---|---|
| Price | $1.46 | $4.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.50 |
| AVG Volume (30 Days) | 55.1K | ★ 92.6K |
| Earning Date | 01-01-0001 | 03-16-2026 |
| Dividend Yield | ★ 17.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | N/A | ★ $6,159,786.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.85 | $1.92 |
| 52 Week High | $13.95 | $16.94 |
Technical Indicators
Market Signals| Indicator | MVO | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 34.73 |
| Support Level | $1.33 | $4.40 |
| Resistance Level | $1.52 | $5.65 |
| Average True Range (ATR) | 0.17 | 0.47 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 21.11 | 22.66 |
Price Performance
Historical ComparisonAbout MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. Its underlying properties consist of MV Partners, LLC's (MV Partners) net interests in all of its oil and natural gas properties, which are located in the Mid-Continent region in the States of Kansas and Colorado. These properties include producing oil and gas wells.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.